SURGE Therapeutics

aid: surge-therapeutics
name: SURGE Therapeutics
description: SURGE Therapeutics is a clinical-stage biotechnology company based in Cambridge, Massachusetts, developing intraoperative
  cancer immunotherapy. Founded on research from Dr. Michael Goldberg's laboratory at Harvard Medical School, the company's
  SURGERx platform is an injectable, biodegradable hydrogel placed directly at the site of surgical tumor resection to provide
  extended, localized release of immunotherapy — addressing the surgery-induced inflammation that suppresses the immune system
  and allows residual disease to reawaken. Its lead program, SRG-514, completed Phase 1 dose escalation in breast cancer patients
  undergoing surgery and is being prepared for a registrational trial, with an additional IND cleared for a Phase 1/2a study
  in bladder cancer. SURGE has raised a $26M Series A and a $32M Series B. It is a therapeutics developer, not a software
  company, and publishes no developer program, API, or machine-readable interface.
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://surgetx.com/wp-content/uploads/2021/06/SURGE_No-Slogan-COLOUR-1024x279.png
url: https://raw.githubusercontent.com/api-evangelist/surge-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-05'
modified: '2026-08-05'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Immunotherapy
- Drug Delivery
- Clinical Stage
- Health
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/surge-therapeutics-domain-security.yml
- type: Website
  url: https://surgetx.com/
- type: About
  url: https://surgetx.com/science/
- type: Team
  url: https://surgetx.com/team/
- type: News
  url: https://surgetx.com/news/
- type: Contact
  url: https://surgetx.com/contacts/
- type: LinkedIn
  url: https://www.linkedin.com/company/surge-therapeutics
- type: SecondaryMarket
  url: https://forgeglobal.com/surge-therapeutics_stock/
x-enrichment:
  date: '2026-08-05'
  status: minimal
  artifacts_added: 1
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: SURGE Therapeutics is a clinical-stage oncology drug developer whose entire web presence is a five-page WordPress
    marketing site (home, science, news, team, contacts); the only machine-readable endpoint on surgetx.com is WordPress core's
    default /wp-json CMS route index, and api./developer./docs./portal.surgetx.com are all NXDOMAIN.
  evidence:
  - url: https://surgetx.com/openapi.json
    status: 404
  - url: https://surgetx.com/.well-known/agent-card.json
    status: 404
  - url: https://surgetx.com/.well-known/security.txt
    status: 404
  - url: https://surgetx.com/llms.txt
    status: 404
  - url: https://api.github.com/orgs/surgetx
    status: 404
  - url: https://surgetx.com/wp-json
    status: 200
  checked: '2026-08-05'